Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O75469

UPID:
NR1I2_HUMAN

ALTERNATIVE NAMES:
Orphan nuclear receptor PAR1; Orphan nuclear receptor PXR; Pregnane X receptor; Steroid and xenobiotic receptor

ALTERNATIVE UPACC:
O75469; Q006P5; Q008C8; Q96AC7; Q9UJ22; Q9UJ23; Q9UJ24; Q9UJ25; Q9UJ26; Q9UJ27; Q9UNW4

BACKGROUND:
Orphan nuclear receptor PXR, also known as the Steroid and xenobiotic receptor, is a crucial transcription factor that responds to endogenous and xenobiotic compounds. It binds and activates transcription of genes crucial for the detoxification and clearance of potentially harmful substances. PXR's activation by compounds like guggulipid and isoflavones underscores its significance in mediating the body's response to a wide array of substances.

THERAPEUTIC SIGNIFICANCE:
Exploring the Pregnane X receptor's function offers a promising pathway to developing novel therapeutic approaches. Its central role in controlling the gene expression of CYP3A4 and ABCB1/MDR1 genes, key players in drug metabolism, positions PXR as a strategic target in enhancing drug safety and effectiveness.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.